Kronos IncorporatedIndrani Ray-Ghosal +1 Copyright Business Wire 2009

Kronos IncorporatedIndrani Ray-Ghosal, +1 Copyright Business Wire 2009. DUBLIN–(Business Wire)–Elan Corporation, plc (NYSE: ELN) today announced that it will present at theGoldman Sachs 30th Annual Global Healthcare Conference in New York, NY, onWednesday, June 10, 2009, at 7:30 p.m British Summer Time; and 2:30 p.m.Eastern Time. Interested parties may access a live audio web cast of the presentation byvisiting the Investor Relations section of the Elan website at ,then clicking on the event icon. Following the live webcast, an archived versionof the presentation will be available at the same URL. About ElanElan Corporation, plc is a neuroscience-based biotechnology company committed tomaking a difference in the lives of patients and their families by dedicatingitself to bringing innovations in science to fill significant unmet medicalneeds that continue to exist around the world.

Elan shares trade on the NewYork, London and Dublin Stock Exchanges. For additional information about thecompany, please visit http:// Elan Corporation, plcMedia:Mary Stutts, 650-794-4403Niamh Lyons, 353-1-663-3602orInvestors:Chris Burns, 800-252-3526David Marshall, 353 1 709 4444 Copyright Business Wire 2009. LOUISVILLE, Ky.–(Business Wire)–Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated tobringing new anti-cancer therapies to market, today announced that it has signedan exclusive license to develop and commercialize small molecule compoundinhibitors of choline kinase, an enzyme discovered to be required for thesurvival of tumorsby scientists at the University of Louisville`s James GrahamBrown Cancer Center (Brown Cancer Center) Brown Cancer Center researchers Drs. Brian Clem, Sucheta Telang, Jason Chesneyand John Trent recently found that removal of the gene for choline kinase causeda block in signals required for the survival of tumors Using computingtechnologies that Dr. Trent developed in Kentucky, they then screened millionsof chemicals and identified one that turned off the enzyme.

This lead chemicalinhibitor of choline kinase caused the death of lung tumors in mice Dr. Chesneystates that, “The discovery of a powerful inhibitor of this new survival enzymecould lead to a new class of chemotherapies.” “ACT is a unique biotechnology company in that we have a rich portfolio ofpotential breakthrough anti-cancer products from which to select through ourinnovative business arrangement with the University of Louisville`s Brown CancerCenter,” said Randall Riggs, President & CEO of ACT. “We are very excited tolicense this product opportunity that may eventually provide cancer patientswith a significant breakthrough treatment against solid and hematologicalcancers.” About Advanced Cancer Therapeutics (ACT):ACT is a for-profit private company dedicated to advancing novel therapeuticsfor the prevention and treatment of cancer. ACT has successfully established aunique and innovative business model with the University of Louisville`s JamesGraham Brown Cancer Center (Brown Cancer Center) whereby ACT is able to obtainexclusive worldwide licenses to novel cancer therapeutics discovered at BrownCancer Center under preset business terms. ACT then fast-tracks thesediscoveries, including the selection process for partnership, commercializationand manufacture, to the pharmaceutical industry, and ultimately to the patientswho need them Led by Dr. Don Miller, the Brown Cancer Center employs over fiftyleading scientists focused on the discovery and advancement of breakthroughcancer therapeutics for patients suffering from cancer.

For more information,please visit About James Graham Brown Cancer CenterThe James Graham Brown Cancer Center is a key component of the University ofLouisville’s Health Sciences Center and UofL Health Care. As the region’sleading academic, research, and teaching medical center, our patients benefitfrom the latest medical advances, often long before they become available innon-teaching settings. The Brown Cancer Center is affiliated with the KentuckyCancer Program and the National Cancer Institute. It is the only cancer centerin the region to use a unified approach to cancer care, with multidisciplinaryteams of physicians working together to guide patients through diagnosis,treatment and recovery. For more information, visit our website Advanced Cancer TherapeuticsRandall B.

Riggs, President & CEO, Copyright Business Wire 2009. Empirix Remains the Service Quality Assurance Leader for EnterpriseOrganizations, Service Providers and Network Equipment Manufacturers Around theWorldBEDFORD, Mass.–(Business Wire)–Empirix Inc., the market leader of service quality assurance solutions for newIP communications, today announced a period of remarkable growth. Empirixextended their global reach and is continuing their momentum by signingadditional new customers and partners, launching multiple product offerings,having received numerous industry awards and expanding the company`s managementteam. The company`s growth, innovation and continued leadership positionsEmpirix to thrive in the evolving service quality assurance market in the comingyear.